Darlene Dobkowski, MA | Authors

Articles

Higher Lenvatinib Dose May Improve HRQoL in RCC

April 02, 2021

The standard dose of lenvatinib, 18 mg per day, demonstrated an improved health-related quality of life and a longer time to deterioration over a lower starting dose of lenvatinib, 14 mg per day, in patients with renal cell carcinoma, according to secondary results from a phase 2 trial.